The deal size was raised to $150M in common stock from $125M in common stock. Morgan Stanley and TD Cowen acted as joint book running managers for the offering.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TCRX:
- TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering
- TScan Therapeutics Advances in Solid and Hematological Cancer Therapy
- TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering
- TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities
- TScan Therapeutics appoints Chrysta Louis M.D CMO
